chrisvoncsefalvay/vaers-outcomes huggingface dataset:
had chills and fever and headache; had chills and fever and headache; had chills and fever and headache; Initial information regarding an unsolicited valid non-serious case received from a consumer (patient) via social media on 06-Dec-2020.  This case involves a patient with unknown demographics who experienced chills, fever (pyrexia) and headache, while the patient received INFLUENZA VACCINE.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medication was not reported.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiration date not reported) via unknown route in unknown administration site.   On an unspecified date, the patient developed  non-serious chills, fever (pyrexia) and headache following the administration of INFLUENZA VACCINE.  It was not reported if the patient received any corrective treatment.  Outcome of the events was unknown, at the time of reporting.  There will be no information available on the batch number for this case.  The reporter assessed the causal relationship with suspect vaccine as related.
15 mins after injection: tachycardic,hypertensive,full body tremors,teeth chattering,facial flushing,lightheadedness
Dizziness, sweating, chills, vomiting. T 98.6, HR 64, R 20.
Pain, swelling, redness on the right arm. Parent called the health center 5/8/2000. Advised to apply cold compressed give Tylenol prn pain. Come in for evaluation. Go to emergency if none.
Flu shot given - Dec. 10, 2019 Sick Dec. 24th, 2019, went to Doc. Dec. 26, 2019 Very tired, Fever of 102, raw sore throat, weak, chills for 12 days. Had to go on amoxicillin for 10 days, because my throat was so raw.
This spontaneous report as received from a registered nurse refers to a patient of unknown age and gender. The registered nurse reported that on 03-NOV-2041, the patient was vaccinated with an expired dose of ZOSTAVAX lot # J011211 (expiration date 31-JUL-2014), 0.65 ml, subcutaneous. No adverse effect reported. No other information was available at this time. Additional information has been requested.
36-48 hrs after injection, developed generalized itching with swollen lips. Tx'd with BENADRYL initially then ZURTEC/ZANTAC for hives.
Sore arm day of vaccine only.  Nausea and vomiting x7 starting at 9:00pm day 3 post vax and lasting until 5:00am on day 4.
Cannot handle the side effects; A spontaneous case was received from a registered nurse on 17MAY2023 regarding a female patient of unknown age who "cannot handle the side effects" (PT: Adverse event) following the administration of oral Vivotif capsules (typhoid vaccine live oral Ty21A; lot number: unknown) for immunisation.  The patient's medical history, concomitant medications, or known allergies were not reported.  It was reported that the patient administered two doses of oral typhoid and was not able to handle the side effects. Therefore, the patient would not be finishing the series of vaccination.  The outcome of the reported event was unknown at the time of this report.  The action taken with the Vivotif with respect to the event was drug withdrawn.  No additional information was provided.  Company comment: It was reported that a consumer took Vivotif for immunisation and could not handle the side effects (adverse event). Further information regarding the event is limited. Considering the case information, the role of Vivotif cannot be ruled out and the causality of adverse event is assessed as possible. The case is considered non serious as per medical assessment.; Sender's Comments: It was reported that a consumer took Vivotif for immunisation and could not handle the side effects (adverse event). Further information regarding the event is limited. Considering the case information, the role of Vivotif cannot be ruled out and the causality of adverse event is assessed as possible. The case is considered non serious as per medical assessment.
Patient received Fluzone influenza vaccine on 10/24/07 at 4pm in left arm. On 10/25/07 injection site was warm to touch. On 10/26/07 at 8:45pm child woke up crying due to pain in left arm. Upon evaluation, arm had 4" x 4" patch of red skin at and below injection site. Arm was also considerably swollen and hot to touch. Arm circumference was measured and affected arm (left)was 1" larger (8.5") than right arm (note: childs predominant arm is the right arm). Child's on call physician contacted and they suggested a visit to after hours clinic for a diagnosis. Child taken to Hospital After Hours Pediatric Clinic and seen by Dr. Diagnosis at time of visit was cellulitis with prescription for Omnicef 200mg BID x 10 days initiated. Within 24 hours of antibiotic initiation the affected site had cooled and within 48 hours the redness and swelling had subsided. Antibiotic treatment to continue for 8 more days at the time this adverse event report was submitted.
Syncopal episode 5 minutes after receiving H1N1 vaccine. Pt supine w/ legs up - 1.
This spontaneous report was received from a pharmacist refers to a 60 year old female patient with phenothiazine and bispho allergy. The patient was not pregnant. On 26-JUN-2014 the patient was vaccinated with ZOSTAVAX, 0.65 ml, subcutaneous, lot # reported as J016258 and expiration date reported as 26-FEB-2015, in the left arm. In June-2014 the patient developed red area in back of left arm (the arm injection was given into) which was warm to touch. On 06-30-2014 the patient was seen in urgent care and prescribed three days of BACTRIM and prednisone. There was not laboratory diagnostics studies performed. The outcome of patient developed red area in back of left arm (the arm injection was given into) which was warm to touch was reported as not recovered/not resolved. Additional information has been requested.
Vaccine was administrated more than 12 hours after first puncture; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine was administrated more than 12 hours after first puncture) in a 68-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042J21A) for COVID-19 vaccination.    No Medical History information was reported.  On 01-Feb-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Feb-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine was administrated more than 12 hours after first puncture). On 01-Feb-2022, EXPIRED PRODUCT ADMINISTERED (Vaccine was administrated more than 12 hours after first puncture) had resolved.  For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication of the patient was not reported.  The patient had not reported any symptoms after the administration of the vaccine.  No treatment information was provided by the reporter.   Date the vial was initially stored in the refrigerator was 31-Jan-2022; date(s) and time(s) vial was first punctured was 31-Jan-2022 at 9 am; the vaccine was administered in the morning of 01-Feb-2022; the vial was the vial stored in the fridge at correct range temperature post puncture and the vial did not undergo any temperature excursions. Total amount of time the vial was exposed to room temperature range (8° to 25°C= 46° to 77°F): as per reporter the nurse took the vial out of the freezer on Friday night and put it on the fridge, which was on appropriate range temperature, then the first puncture was made on 31-Jan-2022 at 9 o'clock.
Presented to the clinic with an itchy, rash on the feet and legs.  (mostly on the feet)
Seamen received SP and anthrax vaccine # 1 02/23/2002. He is a primary vaccine. On day ? c/o red, swollen left arm. increased lymph nodes, increased temp (102) diarrhea. Rx with anti-inflammatory.
Received pneumonia vaccine 9/14/09.  Returned to clinic 9/16/09.  Arm sl swollen.  c/o soreness.  No redness at injection site, however, a 2 inch wide band of redness starting about 3 inches down from injection site and circling around to the inside of the arm appeared 9/15/09. Client was advised to contact her MD.  Client also believes she might have had a pneumonia shot about 10yrs ago.  She did not disclose this prior to receiving the vaccination.  Client was advised to contact her physician.  MD advised her to start benedryl and apply cold packs to the area.
Hurt a little bit on my left arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Hurt a little bit on my left arm) in an 89-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042L20A) for COVID-19 vaccination.     Concomitant products included LEVOTHYROXINE, ATORVASTATIN CALCIUM (LIPITOR), OMEPRAZOLE (PRILOSEC [OMEPRAZOLE]), METOPROLOL and VITAMINS NOS for an unknown indication.    On 25-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Hurt a little bit on my left arm). At the time of the report, PAIN IN EXTREMITY (Hurt a little bit on my left arm) had not resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Relevant concomitant medications included Ellipta.  No treatment information was provided.   This case was linked to MOD-2021-320261, MOD-2021-320262 (Patient Link).
Vaccine error / third Shingrix administered.  Patient came back 2 months later for "second" dose.  Patient doing well, no adverse effect to report after 2 months.
Patient was administered his 2nd dose of shingrix vaccine in the left arm. Within about 1 minute he began to feel light headed. I advised patient to stay in the chair and I got patient some water to see if that would help him. Before he could open the water he stopped talking and began to lean forward. I held patient to prevent him from falling to the ground. I shouted for my technician to call a code white to pharmacy. Patient fainted and was unconscious for about 30 seconds. When patient regained consciousness we had him eat some grapes to get his sugar up and had him drink more water. He then ate a little  peanut butter and jelly cracker. I stayed with patient for 1 hour until he started feeling better. Patient left pharmacy on his on will at about 2 pm on 5/14/2020. The whole incident lasted a little over 1 hour. Patient left pharmacy and went straight home. He reported being fine and said he was going to eat some food. I informed him I would follow up with him later on 5/14/2020. I contacted patient again at 6:15pm on 5/14/2020 and he said he was completely fine and thanked me for checking in with him.
Vaccination was opened on 5/31/2022 between 0700-0800 and medication was administered on 6/1/2022 at 11:50 am.
mom reported that pt had fever 102.5 dec by APAP on day of vax; no other sx; doing well 24 hrs p/vax;
Pt. received dose 1 Pfizer COVID-19 vaccine (EL 9265) on 2/9/21 at a different site. He scheduled dose 2 at another site because he was able to get a date 3 weeks later (today, 3/2/21). When answering pre-clinic questions, he noted dose 1 was Pfizer. He received the vaccine today and as he was driving home, it was noted on his vaccine card that today's does was Moderna. Advised pt that dose does not need repeating and communicated to vaccination site to determine root cause and take steps to prevent similar error in future.
started crying high pitch scream; cried fro 3 hrs refused to eat; was given APAP; no fever; refused to respond to any comfort measures;
Headache; Fatigue; This case was reported by a physician via call center representative and described the occurrence of headache in a adult female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced headache and fatigue. On an unknown date, the outcome of the headache and fatigue were recovered/resolved.   It was unknown if the reporter considered the headache and fatigue to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. After receiving 1st doses of Shingrix, the patient experienced headache and fatigue.  Health care practitioner described the headaches and fatigue had not gotten any better or worse since they began. Health care practitioner did not have lot number or expiration date of doses of Shingrix. No additional information provided. This is one of 4 cases, reported by the same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021094723:case for husband 2nd dose US-GLAXOSMITHKLINE-US2021AMR095072:same reporter US-GLAXOSMITHKLINE-US2021094721:same reporter
Halfway down the elbow appeared a huge [red hot] swollen reaction; Halfway down the elbow appeared a huge [red] hot [swollen] reaction; Halfway down the elbow appeared a huge red [hot swollen] reaction; Halfway down the elbow appeared a huge [red hot swollen] reaction with itching; This is a spontaneous case, initially received from other health professional (Nurse) on 26-Nov-2018, concerning a 50-year-old, adult female patient.  The patient had no medical history and concomitant medications.  On 16-Oct-2018, the patient was administered Afluria Quadrivalent [influenza vaccine, dose: 0.5 ml, route of administration: intramuscular, anatomical location: deltoid, batch number: YF37005 and expiry date: 17-May-2018] for active immunization against influenza.  On the same day, within an hour or two after the administration of the vaccine, the patient had a reaction. It was reported that halfway down to the elbow, a huge red, hot, swollen reaction with itching was appeared with no pain. It affected above the elbow, a halfway up the arm but not the deltoid. There was no swelling of the airways. The patient was treated with anti-histamines and she got better. It was reported that, the patient was not hospitalized, and it looked like an Arthus-type reaction, but the patient did not receive any tetanus or diphtheria vaccines, received only the Afluria Quadrivalent vaccine.  The outcome of the events was recovered on 18-Oct-2018.  The reporter assessed this case as non-serious and the causality of the events as related to suspect vaccine.  Non-significant follow up received from the reporter (med comm) on 18-Feb-2019: It was reported that, it was tried to reach the reporter on 18-Jan-2019 but were unable to obtain the requested information. The Med info number (SEQ19-00376) was added in additional information tab. No changes were made in the narrative.  Significant case amendment (26-Nov-2018): The description to be coded for the event verbatim "Halfway down the elbow appeared a huge [red hot] swollen reaction" was changed from 'swelling of elbow' to 'swelling arm' in the event tab. The case comment was amended accordingly.; Reporter's Comments: A 50-year-old female patient experienced swelling arm, localized feeling of warmth, redness and itching, within an hour or two after the administration of the suspect vaccine Afluria Quadrivalent. The company assessed the causality of the events as related to the suspect vaccine due to plausible temporal relationship between the suspect vaccine and the events.
Right thalmus Cerebral Vascular Accident, unspecified mechanism, left arm and face numbness
Fever 102.8, Chills, Severe back pain and hip pain, muscle aches, breast pain (still happening), Chest pain, Brain fog
pt recvd vax 29JAN96 & started w/severe hives on 8FEB96 requiring visit to MD;rash covered entire body;started Medrol dose pack 9FEB96;rash resolving 14FEB96;ate shell fish noc a/developing rash
About 1 hour and 15 minutes prior to receiving Menatra and Gardasil vaccinations in our office, the patient felt acute onset of throat tightness, throat burning, flushed face and trouble breathing. 05/30/07-records received-5/27/07-trouble breathing. shortness of breath. flushed face. lips slightly swollen. DC: anaphylactic reaction most likely to either Gardasil or Menactra This is in follow-up to report(s) previously submitted on 6/14/2007. Initial and follow-up information has been received from a physician, his office manager and an allergist via medical records concerning an 18 year old (previously reported as 17 year old) female with no known drug allergies and a history of nasal congestion and sneezing after exposure to cut grass who on 25-MAY-2007 was vaccinated IM with the first 0.5mL dose of GARDASIL (lot #657737/0522U) and concomitant suspect therapy MENACTRA (lot #U2278AA). Additionally, information has been received through the Freedom of Information Act pertaining to this case. It was reported that the patient left the physician's office feeling fine after the vaccinations, and subsequently, returned home. The patient ate a turkey sandwich and a kiwi, and "I hour after receiving the vaccine", the patient experienced an acute onset of throat tightness, throat burning, flushed face and trouble breathing. The patient returned to the physician's office with throat tightness, throat burning, flushed face, shortness of breath and lips were slightly swollen. The patient was diagnosed with an anaphylactic reaction and was treated with one EPI-PEN injection, prednisone, 60 mg and BENADRYL, 50 mg. The patient's breathing returned to normal, and subsequently, the patient recovered from the anaphylactic reaction. On 18-JUN-2007, the patient was seen by an allergist who reported that percutaneous skin testing was performed on the patient and revealed positive reactions to kiwi and grass pollen. The patient was diagnosed with a kiwi allergy and grass pollen allergy with seasonal allergic rhinitis. ImmunoCap allergy testing to kiwi, other fruits, pollens and Latex was also performed on the patient (results pending). The patient was instructed on the proper technique and indications for EPI-PEN use and follow-up was pending laboratory results. The reporting physician considered the anaphylactic reaction to be a disabling immediately life-threatening and medically significant event and felt it was most likely related to either therapy with GARDASIL or MENACTRA, although, the allergist felt that the "vaccines were not likely the cause of her reaction" and recommended that an attempt to proceed with the GARDASIL series "can be done in a closely monitored and equipped setting." A standard lot check investigation was performed. All in-process quality checks for the lot number in question were satisfactory. The lot met the requirements of the Center for Biologics Evaluation and Research and was released. Additional information is not expected.
The vial was initially stored in the refrigerator on 08-Jul-2022 and was administer on 11-Aug-2022.; No adverse event; Administered Moderna COVID-19 Vaccine after 30-day use by date.; This spontaneous case was reported by a physician assistant and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Administered Moderna COVID-19 Vaccine after 30-day use by date.), PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 08-Jul-2022 and was administer on 11-Aug-2022.) and NO ADVERSE EVENT (No adverse event) in a 4-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AS1414B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 11-Aug-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .25 milliliter. On 11-Aug-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Administered Moderna COVID-19 Vaccine after 30-day use by date.). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 08-Jul-2022 and was administer on 11-Aug-2022.) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Administered Moderna COVID-19 Vaccine after 30-day use by date.), PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 08-Jul-2022 and was administer on 11-Aug-2022.) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Administered Moderna COVID-19 Vaccine after 30-day use by date.) and PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 08-Jul-2022 and was administer on 11-Aug-2022.).    No concomitant medications were reported.   The healthcare professional was not aware of any symptoms for any patient after the vaccine was given.  No treatment details were reported.
This spontaneous report was received from a healthcare worker and refers to unspecified number of patients of unknown age and gender. Concurrent conditions, medical history, concomitant therapies and known allergies were not reported. On unspecified dates since 30-JUN-2015, the patients were vaccinated with unknown number of doses of GARDASIL 9 (lot # K026247, an expiration date 29-JAN-2017; dose, route of administration and anatomical location were not reported), which were improperly stored. No adverse effects were reported. This is one of the several reports received from the same reporter. Additional information has been requested.
Developed rash 1 day after MMR and then 2 d. later was screaming every hr at night for 1 month and then she started head banging and developed "black outs" - blacked out several times a day. Lasted about 1 month. Has peds neurology follow-up scheduled. Then noted repetitive behaviors.
vomiting; Chills; Nausea; headache; Diarrhea; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (Diarrhea), VOMITING (vomiting), CHILLS (Chills), NAUSEA (Nausea) and HEADACHE (headache) in an 86-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007D21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history).    On 26-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Mar-2021, the patient experienced DIARRHOEA (Diarrhea). On 27-Mar-2021, the patient experienced VOMITING (vomiting), CHILLS (Chills), NAUSEA (Nausea) and HEADACHE (headache). On 27-Mar-2021, DIARRHOEA (Diarrhea), VOMITING (vomiting), CHILLS (Chills), NAUSEA (Nausea) and HEADACHE (headache) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications were not reported. Treatment details not provided
Left thigh swollen from groin area down to knee, significant larger that the right thigh, red but not hard.
Patient was given shot lower than deltoid muscle.  She returned the day following the vaccine adminsitration to report. She had no pain and no radiating pain. She was evaluated at the pharmacy and told to report to doctor if anything arises and if she felt she needed another dose.
pt recvd vax & approx 1030AM according to mom noticed pt lt arm was swollen, red & arm to touch on Sunday 10APR; mom states swelling had spread to 1" above the inject site & down past the elbow about 1" and was 3-4" wide;